Introduction
============

Chronic kidney disease (CKD) develops over time and ultimately leads to end-stage renal disease. Uremic cardiomyopathy and muscle atrophy are critical complications for CKD-related disastrous outcomes [@B1], [@B2]. Cardiomyopathy accounts for approximately 50% of CKD deaths [@B3]. Muscle wasting occurs in almost every type of CKD and is an independent risk factor for CKD-induced morbidity and mortality [@B4], [@B5]. Current treatment strategies offer improved quality and length of patient life but are not effective in curing or reversing either cardiomyopathy or muscle wasting associated with CKD.

Uremic cardiomyopathy is independent of primary/intrinsic cardiomyopathies and other atherosclerotic coronary-related heart disease. In fact, atherosclerotic coronary disorders are decreased in CKD patients compared with the normal population [@B6]. CKD-induced uremic cardiomyopathy is characterized by cardiac fibrosis and heart failure, which are closely related to insulin resistance [@B1]. Uremic cardiomyopathy has a higher rate of sudden cardiac death than does atherosclerotic coronary disease [@B7].

Insulin resistance is an acknowledged risk factor for cardiac disease related to CKD [@B8], [@B9]. During a study of 1187 first hospitalization heart failure patients, the investigator found that insulin resistance predicts and precedes the development of chronic heart failure [@B9]. In addition, insulin resistance is positively correlated with heart function decline [@B10]. A widely used antagonist of insulin resistance, metformin, can improve left ventricular function and reduce myocardial lipid accumulation and cardiac fibrosis [@B11]. Blocking insulin resistance with metformin results in 13% lower mortality compared with therapies to increase insulin sensitivity [@B12]. Insulin resistance causes heart problems through multiple mechanisms. It can downregulate sodium-calcium exchange, decrease myosin ATPase activity and upregulate angiotensin-II in the heart, resulting in reduced cardiac efficiency [@B13]. Insulin resistance is also a critical contributor to skeletal muscle atrophy in CKD and other metabolic diseases by decreasing protein synthesis, increasing protein degradation and limiting skeletal muscle regeneration [@B2], [@B14].

In humans, insulin regulates many metabolism processes by influencing glucose metabolism, fat synthesis and fatty acid esterification, increasing protein synthesis through control of amino acid uptake, altering DNA replication, and modifying numerous enzyme activity states [@B15]. Our group found that insulin resistance induces muscle atrophy by increasing protein degradation in skeletal muscle [@B16]. Insulin regulates protein metabolism through the insulin/IGF-1 signaling pathway, which includes the insulin-like growth factor-1 (IGF-1), insulin receptor substrate, phosphoinositide 3-kinase (PI3K), GSK/Akt and FoxO cascade [@B15]. Akt plays a central role in this insulin-signaling pathway. Phosphorylation of Akt at serine 473 indicates activation and leads to insulin sensitivity. Decreased phosphorylation at this site leads to insulin resistance. Akt and GSK-3β activity are reciprocal regulators of the insulin signaling pathway. Activation of GSK-3β by tyrosine-216 phosphorylation induces insulin resistance, whereas serine (9/21) phosphorylation inhibits GSK-3β, leading to increased insulin sensitivity [@B17]. Normally, Akt inhibits GSK-3β activity, resulting in increased insulin sensitivity [@B18]. Under CKD conditions, Akt activation is inhibited by uremic toxins, and the resulting increased GSK-3β activity leads to insulin resistance, impaired glucose and lipid metabolism and the development of uremic cardiomyopathy [@B1]. FoxO1 is another important factor that contributes to uremic muscle wasting. Activation of FoxO by de-phosphorylation induces muscle wasting along with transcriptional upregulation of E3 ubiquitin ligases, cardiac hypertrophy and fibrosis [@B19], [@B20].

Recent studies have shown that microRNAs (miRs) are important regulators of metabolism during development and disease [@B21]. Many miRs have been linked to regulation of the insulin signaling pathway and have led to some new treatment strategies using these miRs. *miR-26a* has been suggested as a therapeutic target for traditional atherosclerotic cardiac disease [@B22], but it is not clear whether it can limit CKD-induced muscle atrophy and uremic cardiomyopathy. A major challenge in using synthetic miRs for treatment purposes is that exogenously added miRs are quickly degraded by high levels of ribonuclease activity in plasma or are rapidly cleared by phagocytosis, renal filtration or bile excretion resulting in minimal tissue accumulation and minimal therapeutic effectiveness [@B23]. These drawbacks could be overcome by using exosomes as microRNA carriers. Because exosomes stabilize miRs and are non-cytotoxic and non-mutagenic to the recipient, they are longer lived compared to viral or liposome-based gene delivery vehicles [@B24].

Here, we show the impact of intramuscular injection of exosomes carrying *miR-26a-5p* on muscle atrophy and cardiac fibrosis in CKD mice. We investigated the outcome of exogenous *miR-26a* on CKD-induced muscle wasting, insulin signaling and heart function in uremic mice. We also used fluorescently labeled exosomes/*miR-26a* to track the exosomes *in vivo*. Our findings provide new insights into how *miR-26a* participates in the control of skeletal muscle mass and cardiac fibrosis.

Results
=======

*miR-26a* was decreased in the heart and skeletal muscle of CKD mice
--------------------------------------------------------------------

In exploring new therapeutic targets for treating cardiomyopathy associated with CKD, we performed miRNA deep sequence analysis from heart samples of CKD mice. The data revealed 56 miRs that were altered in CKD mice compared with sham-operated pair-fed mice (**Figure [1](#F1){ref-type="fig"}A** and **Table [S1](#SM0){ref-type="supplementary-material"}**). These included *miR-26a,* which was decreased 37.2% in CKD heart. We first used qPCR to determine whether *miR-26a* was expressed in major organs of normal mice and found that *miR-26a* was mainly expressed in skeletal muscle and heart (**Figure [1](#F1){ref-type="fig"}B**). Further qPCR analysis showed that *miR-26a* levels were 61% lower in the cardiac muscle of CKD versus sham mice (**Figure [1](#F1){ref-type="fig"}C**). When we examined whether CKD influences *miR-26a* expression in skeletal muscle, we found that *miR-26a* was decreased by 35% in skeletal muscle of CKD vs. sham mice (**Figure [1](#F1){ref-type="fig"}D**).

Uremic serum increased catabolic signaling and profibrotic proteins
-------------------------------------------------------------------

To further study the impact of CKD stress on *miR-26a*, we treated skeletal muscle satellite cells and H9C2 cardiac myoblasts with 5% mouse serum from CKD or normal control mice for 24 hours. We isolated RNA from these cells and probed for the expression of *miR-26a* by qPCR. Treatment with uremic serum resulted in a 31% decrease in *miR-26a* in skeletal muscle satellite cells (**Figure [2](#F2){ref-type="fig"}A**) and a 44% decrease in H9C2 cardiac myocytes (**Figure [2](#F2){ref-type="fig"}B**). These results suggest that a decrease in*miR-26a* in skeletal muscle and heart could be due to uremic toxicity. To explore the impact of uremic serum on protein changes, we measured Akt, PTEN and TGFβ1 in uremic serum-treated cells by western blot. The uremic serum decreased Akt phosphorylation and increased PTEN protein in satellite cells (**Figure [2](#F2){ref-type="fig"}C**). Similar decreases in Akt phosphorylation were also observed in H9C2 cells (**Figure [2](#F2){ref-type="fig"}D**). TGFβ1 was increased by uremic serum, suggesting increased fibrosis signaling. These results suggest that uremic serum is critical for the induction of insulin resistance and is associated with decreasing *miR-26a*.

Exosomes with encapsulated *miR-26a* and muscular surface target peptide (MSTP) surface peptide were generated
--------------------------------------------------------------------------------------------------------------

Since microRNA has a relatively short life and exosomes can stabilize microRNA [@B25], we used exosome-encapsulated microRNA to overexpress *miR-26a in vivo* (**Figure [S4](#SM0){ref-type="supplementary-material"}**). First, a *pLamp2b/MSTP* vector was constructed. This vector contained *lysosomal-associated membrane protein 2b (Lamp2b)*, which is an exosomal membrane protein gene [@B26], fused with 3-muscle surface targeting peptide SKTFNTHPQSTP. This peptide has strong cardiac muscle targeting ability [@B27]. Second, an adenovirus containing a precursor *miR-26a* gene (Ad-miR-26a) was generated. Third, satellite cells were transfected with pLamp2b/MSTP and transduced with Ad-miR-26a or control virus (Ad-empty) in exosome-free medium. In this case, the exosomes secreted from satellite cells should contain *miR-26a* with muscle target ability. Last, the pLamp2b/MSTP-miR-26a enriched exosomes (Exo/*miR-26a*) and pLamp2b/MSTP-ctrl exosomes (Exo/ctrl) were isolated from the conditioned medium of cultured cells. The concentration and size of the collected exosomes were measured using a NanoSight instrument (**Figure [S1](#SM0){ref-type="supplementary-material"}**). The average size of the isolated exosomes was 89 ± 1.8 nm. The exosome protein marker TSG101 was absent in the transduced cells but present in the Exo/miR-ctrl and Exo/*miR-26a* isolated from conditioned medium (**Figure [S3](#SM0){ref-type="supplementary-material"}**). Real-time qPCR showed that *miR-26a* was increased 35-fold in Exo/*miR-26a* vs. Exo/ctrl (**Figure [S5](#SM0){ref-type="supplementary-material"}**). We labeled Exo/*miR-26a* with DiR (1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide), a fluorescent tag for exosome surface lipids (D12731; Invitrogen, Carlsbad, CA, USA), before intramuscular injection and imaged the legs with an In-Vivo Xtreme camera system (Bruker, Billerica, MA, USA). We observed a dose-dependent increase in fluorescence intensity in the injected TA muscles (**Figure [S6](#SM0){ref-type="supplementary-material"}**).

*miR-26a-5p* attenuated CKD-induced muscle atrophy
--------------------------------------------------

The CKD experimental procedures are shown in **Figure [3](#F3){ref-type="fig"}A**. To examine whether enhancing *miR-26a* in the muscles might prevent muscle wasting, Exo/*miR-26a* and Exo/ctrl were injected into the TA muscle of CKD mice once per week beginning immediately following the second CKD surgery. Skeletal muscle and heart were harvested 8 weeks after initiation. The exogenously added Exo/*miR-26a* replenished *miR-26a* in skeletal muscle to control levels (**Figure [3](#F3){ref-type="fig"}B**) as well as limited CKD-induced mouse body weight and muscle weight loss (**Table [1](#T1){ref-type="table"}**). This result was supported by the improved muscle cross section area. Consistent with our previous studies [@B2], the muscle cross section area was decreased by CKD (**Figure [3](#F3){ref-type="fig"}C**). Conversely, overexpressing *miR-26a* caused a shift to a large cross sectional area when compared with results in CKD muscles injected with the Exo/ctrl (**Figure [3](#F3){ref-type="fig"}D**). To examine the possible mechanisms by which overexpression of Exo/*miR-26a* attenuates muscle mass loss in CKD mice, we examined the proteins related to the insulin-IGF-1/Akt/FoxO signaling pathway. The active form of Akt, phosphorylated at serine-473, was decreased in CKD, indicating decreased insulin sensitivity. Similarly, CKD decreased the amounts of serine-21/ 9-phosphorylated GSK-3β and tyrosine-24-phosphorylated FoxO1, resulting in their activation and increasing insulin resistance. Consequent to FoxO1 activation, FBXO32/atrogin-1 and TRIM63/MuRF1, two FoxO-targeted E3 ubiquitin ligases, were increased (**Figure [3](#F3){ref-type="fig"}E**). Provision of *miR-26a* in TA muscle reversed all these changes (**Figure [3](#F3){ref-type="fig"}**) and should lessen insulin resistance, which suggests a mechanism for limiting skeletal muscle loss.

Intramuscular injection of Exo/*miR-26a* attenuated uremic cardiomyopathy in CKD mice
-------------------------------------------------------------------------------------

Since Exo/*miR-26a* contains a muscle-specific surface peptide with the potential to target cardiac muscle [@B27], we hypothesized that these exosomes would carry *miR-26a* to the heart. To verify whether skeletal muscle injection of Exo/*miR-26a* could transfer *miR-26a* to the heart or other distant organs, we stained Exo/*miR-26a* with 1 μmol/l fluorescent tracer DiR before intramuscular injection, and one week later, we imaged dissected organs with the In-Vivo Xtreme camera system. Dissected organs from uninjected normal mice (right group), sham mice injected with Exo/*miR-26a* (center group) and CKD mice injected with Exo/*miR-26a* (left group) are shown in **Figure [S7](#SM0){ref-type="supplementary-material"}**. In the injected CKD mice, fluorescence was observed not only in injected TA muscle but also in contralateral uninjected TA muscle and heart (**Figure [4](#F4){ref-type="fig"}A**). In the injected sham mice, fluorescence was observed in the same organs; however, the labeled exosome fluorescence intensity was higher in CKD hearts than in sham hearts (**Figure [4](#F4){ref-type="fig"}B**). The expression of *miR-26a* was higher in CKD hearts than in hearts from sham-operated mice (**Figure [S8](#SM0){ref-type="supplementary-material"}**), which suggests that the uremic heart has a higher capacity to recruit Exo/*miR-26a*. We measured the expression of *miR-26a* in the hearts of CKD mice with Exo/*miR-26a* or Exo/MiR-ctrl intramuscular injections. The expression of *miR-26a* was increased 1.8-fold in CKD mouse heart from the Exo/*miR-26a*-injected animals versus the mice receiving Exo/ctrl injection (**Figure [4](#F4){ref-type="fig"}C**). We next determined if Exo/*miR-26a* was increased in the circulation. We found a 2.1-fold increase in *miR-26a* in serum exosomes from CKD mice injected with Exo/*miR-26a* versus Exo/ctrl administration (**Figure [4](#F4){ref-type="fig"}D**). To discover whether circulating exosomes that are enriched in *miR-26a* have the potential to attenuate insulin resistance and inhibit fibrosis, we measured FoxO1 phosphorylation and TGFβ1 in serum exosomes. FoxO1 phosphorylation was decreased, and TGFβ1 and PTEN were increased in the exosomes from CKD mouse serum. These changes were blunted in serum exosomes from CKD mice that were treated with Exo/*miR-26a* (**Figure [4](#F4){ref-type="fig"}E**). Treatment of CKD mice with Exo/ctrl did not show the beneficial blunting of these protein responses. These data suggest that 1) damaged heart has a tendency to recruit more exosomes/miR than a healthy heart; 2) intramuscular injection of Exo/*miR-26a* can increase *miR-26a* expression in the heart; and 3) in serum, *miR-26a*-enriched exosomes carry signaling proteins that can limit insulin resistance.

CKD mouse heart showed significant uremic cardiomyopathy, as evidenced by the increased ratio of heart weight to body weight (**Table [2](#T2){ref-type="table"}**). Exogenous *miR-26a* reduced CKD-induced increases in the heart/body weight ratio. CKD mice also had significantly increased cardiac fibrosis *vs.* sham mice, as demonstrated by Masson\'s trichrome staining. Collagen deposits (indicated by blue staining in heart sections) were increased 43-fold in the hearts of CKD mice, and intervention with *miR-26a* in CKD mice reduced the elevated collagen accumulation by 50% compared to CKD with Exo/miR-ctrl (**Figure [5](#F5){ref-type="fig"}A**). The interstitial matrix protein marker fibronectin is a signature for myofibroblast activation and was significantly increased in the heart of CKD mice. The provision of *miR-26a* to CKD mice decreased the amount of fibronectin (**Figure [5](#F5){ref-type="fig"}B**) and also partially limited the CKD-induced increase in two fibrotic protein markers, collagen 1A1 and connective tissue growth factor (CTGF), in the heart (Figure [5](#F5){ref-type="fig"}C). These results suggest that intramuscular injection of Exo/*miR-26a* can decrease cardiac fibrosis in CKD mice.

*miR-26a* limited insulin resistance resulting in improved cardiac function
---------------------------------------------------------------------------

Insulin/IGF-1 signaling pathway-related proteins were evaluated by western blot. The phosphorylation levels of ser-21/9 in GSK-3β and thr-24 in FoxO1 were decreased by CKD, resulting in increased insulin resistance. The increase of pser-473-Akt by Exo/*miR-26a* suggested increasing insulin sensitivity (**Figure [6](#F6){ref-type="fig"}A**). Exogenous *miR-26a* increased both pser-21/9-GSK-3β and pthr-24-FoxO1, limiting insulin resistance. In addition, we determined whether overexpression of *miR-26a* might downregulate FoxO1 expression since FoxO1 was predicted as a target of *miR-26a-5p* by *in silico* analysis (TargetScan, PITA, miRanda). We performed a luciferase reporter analysis in cultured skeletal muscle satellite cells using a reporter construct in which the luciferase coding sequence was fused to the 3\'-UTRs (position 3358 - 3364 nt) of human *FoxO1* (*pLuc.miR-26a/FoxO1-3\'UTR*).*miR-26a* markedly repressed luciferase activity in cells transfected with *pLuc.miR-26a/FoxO1-3\'UTR (Fox/3\'UTR)*. Mutation of the *miR-26a* target sites abrogated *miR-26a*-induced repression of luciferase activity (**Figure [6](#F6){ref-type="fig"}B**). These data suggest that *FoxO1* is a direct target of *miR-26a*.

Cardiac function was evaluated by echocardiography (**Table [2](#T2){ref-type="table"}** & **Figure [6](#F6){ref-type="fig"}C**). In CKD mice, left ventricle (LV) end-diastolic diameter (LVEDD), LV end-systolic chamber dimensions (LVESD), and left ventricular volume in diastole and systole (LV vol-d and LV vol-s) were all significantly increased in the hearts of CKD mice. These changes were accompanied by a decrease in the percentage of ejection fraction (%EF) and fractional shortening (FS) in CKD mice. Provision of *miR-26a* improved all of these CKD-induced changes in cardiac function parameters. The echocardiographic results suggest that *miR-26a* intervention improves cardiac function.

To demonstrate that MSTP is important in Exo/*miR-26a* accumulation in the heart, we generated additional exosomes encapsulated *miR-26a* without MSTP (Flag-Exo/*miR-26a*). We injected both Flag-Exo/*miR-26a* and MSTP-Exo/*miR-26a* into the TA muscles of CKD mice and measured *miR-26a* expression in circulation exosomes and in the heart. The expression of *miR-26a* in serum exosomes from the two groups of mice was not significantly different (**Figure [6](#F6){ref-type="fig"}D**). However, the expression of *miR-26a* in the cardiac muscle of MSTP-Exo/*miR-26a*-injected mice was significantly higher than in hearts from Flag-Exo/*miR-26a*-injected mice (**Figure [6](#F6){ref-type="fig"}E**). Interestingly, the *miR-26a* that accumulated in the CKD heart was significantly higher than that in the sham-operated heart. These data indicate that MSTP plays an important role in targeting microRNA to the injured heart. To show that the fluorescence accumulated in the various tissues was an indication of Exo/*miR-26a* or Exo/miR-ctrl, not just nonspecific spreading of unattached dye, we injected fluorescent lipophilic DiR without exosomes into TA muscle and looked for fluorescence throughout the body. A signal was detected at 1, 2 and 4 weeks after DiR injection *in vivo*. Analysis of organs *ex vivo* showed that fluorescence was confined to muscle and not detected in other organs, including the kidney at all times (**Figure [S9](#SM0){ref-type="supplementary-material"}**).

Discussion
==========

In this study, we showed that under CKD stress conditions, skeletal muscle atrophy and uremic cardiomyopathy are related to a decrease in *miR-26a*. When we injected exosomes encapsulating *miR-26a* with the muscle-targeting peptide MSTP into skeletal muscle of CKD mice, we observed attenuated skeletal muscle wasting but also decreased evidence of cardiomyopathy. Our data indicate that overexpression of *miR-26a* achieves these benefits by limiting insulin resistance. In addition, we determined that *FoxO1* is a direct target of *miR-26a*.

Our findings that exogenous application of *miR-26a* increases muscle cross section area, diminishes CKD-induced cardiac fibrosis and improves heart function strongly suggest that these miR-related changes are involved in the limitation of insulin resistance. Many systems and renal-specific factors contribute to muscle atrophy and uremic cardiomyopathy in CKD, including metabolic acidosis, inflammation, and increased oxidant stress [@B1], [@B28]. However, insulin resistance is recognized as a major and common mechanism causing both muscle wasting and cardiomyopathy in CKD [@B1]. Our previous studies proved that the downregulation of insulin/IGF-1 signaling is the major cause of muscle wasting in CKD because it increases accelerated protein degradation by activating the ubiquitin proteasome pathway [@B16], [@B29]. In the current study, we found that several proteins closely related to the insulin/IGF-1 cascade were altered by *miR-26a-5p*. Activation of Akt by *miR-26a* upregulates the insulin/IGF-1 signaling pathway. Inactivation of FoxO1 and GSK-3β by *miR-26a* lessens insulin resistance. Other investigators have also observed that obesity-induced decreases in *miR-26a* attenuate insulin sensitivity [@B30], overexpression of *miR-26a* inhibits GSK-3β activation [@B31], and *miR-26a* has important implications for cardiovascular repair [@B32].

In non-CKD pathologies, the cardiac response to increased phospho-Akt is to undergo postnatal coronary angiogenesis and cardiac hypertrophy [@B33]. However, in the heart of CKD animals, we and others have found that phospho-Akt protein is decreased and FoxO is activated [@B34]. Importantly, CKD promotes the development of specific forms of cardiomyopathy that are independent of increased coronary artery disease or hypertension. In CKD pathology, decreased phospho-Akt and increased FoxO1 can cause increased insulin resistance with a disadvantageous outcome. In an ischemia reperfusion injury model, Rota et al. showed that nuclear-targeted overexpression of Akt1 did not induce cardiac hypertrophy but instead increased the number of cardiomyocytes, increased contractility and protected against ischemia-reperfusion injury [@B35].

Insulin resistance can induce cardiac fibrosis, which is another consequence of CKD. In the uremic heart, increased expression of profibrosis mediators such as TGFβ and CTGF causes increased collagen levels and results in interstitial fibrosis, which contributes to diastolic dysfunction, ventricular stiffness, and cardiac dysrhythmias [@B36]. Our study demonstrates that *miR-26a* intervention reduces CTGF abundance and restricts collagen deposition in the heart. Koga et al. showed that *miR-26a* inhibits TGFβ by directly targeting CTGF [@B37]. This is consistent with our findings that show that cardiac fibrosis is inhibited by *miR-26a*.

Studies have found that *miR-26a* has multiple targets that are involved in fibrosis and insulin resistance, such as GSK-3β, PTEN, CTGF and collagen I [@B31], [@B38], [@B39]. In this study, we identified a novel target of *miR-26a*, *FoxO1*. The following is evidence to prove this outcome: provision of *miR-26a* in skeletal muscle decreased FoxO1 protein *in vivo* (**Figure [3](#F3){ref-type="fig"}E** and **Figure [6](#F6){ref-type="fig"}A**). Using a luciferase reporter assay, we found direct binding of *miR-26a* to the 3\'-UTR of *FoxO1* (**Figure [6](#F6){ref-type="fig"}B**). Both our *FoxO1* target results and the target studies from us and others provide reasonable evidence that intervention with *miR-26a* can limit insulin resistance and fibrosis. All microRNAs have the potential for off target effects due to the multiplicity of their targets. According to the literature, *miR-26a* suppresses cell proliferation in esophageal cancer cells and tenon capsule fibroblasts [@B40]. In addition, one study found that *miR-26a* decreases inflammation-mediated tumorigenesis and metastasis of cancer cells [@B41]. Our results indicating that muscle size and mass increased in response to *miR-26a* suggest that this miR is not inhibiting or suppressing cell proliferation, i.e., it does not show the same trend as the previously observed off-target effects. However, we cannot rule out the possibility that *miR-26a* could affect other tissues that are not the subject of our investigations.

Another important outcome of these studies is the determination that the use of a muscle-specific targeting peptide is a good approach to direct microRNA to skeletal muscle and heart. Exosomes are carrier vehicles. Both pre-miRNAs and mature miRNAs are located in exosomes and have been determined to be quite stable [@B42]. In a clinical trial, patients tolerated exosome injection for up to 21 months [@B43]. In this study, we constructed a new exosome targeting vector to promote the accumulation of exosome-packaged miRs to specific destinations. Using a muscle-specific target peptide, SKTFNTHPQSTP, in the structure of the exosomes/microRNA caused them to preferentially move to skeletal muscle and heart. This vector contains *Lamp2b* and *MSTP*. Since *Lamp2b* is ubiquitously expressed on the surface of exosomes, it facilitates the fusion of target peptides to the surface of exosomes and endows exosomes with targeting ability [@B27]. Interestingly, we also found that an injured organ has a higher capacity to recruit exosomes/miR than do normal organs because *miR-26a* expression is much higher in CKD hearts than in normal sham control hearts after matched intramuscular injections of Exo/*miR-26a* (**Figure [4](#F4){ref-type="fig"}A** and**Figure [4](#F4){ref-type="fig"}B**). We believe that the damaged tissue creates a hierarchy for the recruitment of exosomes. The CKD heart has damage, giving it higher priority to collect therapeutic exosomes than healthy heart in sham mice. This could involve the response of injured organs to induce secretion of inflammatory cytokines, leading to increased capillary permeability. Any increased vascular permeability could result in increased exosome uptake. Another potential mechanism for increased exosome uptake is fusion. Fusion efficiency is enhanced in an acidic environment. A hallmark of CKD is tissue acidosis, which could increase exosome uptake [@B44]. The mechanisms of these phenomena require future studies.

In conclusion, exogenous *miR-26a* not only attenuated skeletal muscle atrophy but also ameliorated uremic cardiomyopathy by targeting multiple mRNAs. These findings suggest that *miR-26a* could be useful as a therapeutic agent for increasing insulin sensitivity and inhibiting muscle wasting and uremic cardiomyopathy.

Methods
=======

CKD mouse model and treatment: The experiments were approved by the Emory University IACUC (protocol 4000152). Mice (C57BL/6J) were purchased from Jackson Laboratories (Bar Harbor, ME, USA). The CKD model was obtained through a two-step 5/6 nephrectomy [@B14]. We started Exo/*miR-26a* or Exo/control tibialis anterior (TA) injection after the second CKD surgery (40 µg of exosomes each time, once per week for a total of 8 weeks).

Generation of exosome-encapsulated *miR-26a* and exosome purification: A *pLamp2b/MSTP* vector was constructed by the Genomics core of Emory University. Satellite cells were grown to 60% confluence in DMEM/F12 culture medium containing 20% fetal bovine serum [@B14]. The *Lamp2b/MSTP* vector was transfected into satellite cells using the Effectene transfection reagent (Qiagen, Valencia, CA, USA). Six hours after transfection, the cells were transduced with Ad-miR-26a (adenovirus containing *miR-26a* processor sequences) to produce exosome-encapsulated *miR-26a* (Exo/*miR-26a*). Control cells were transduced with Ad-empty for production of MSTP-exosome-control (Exo/ctrl). Exosome-free medium was used to replace the growth medium to allow exosome secretion for 48 hours. Last, the *pLamp2b/MSTP-miR-26a* enriched exosomes (Exo/*miR-26a*) and *pLamp2b/MSTP*-ctrl exosomes (Exo/ctrl) were isolated from the conditioned medium of cultured cells and resuspended in PBS. Exosomes were purified by several centrifugation and filtration steps as described previously [@B45]. Exosome size and concentration were analyzed using a NanoSight instrument and an electro-microscope (**Figure [S1](#SM0){ref-type="supplementary-material"}** and**Figure [S2](#SM0){ref-type="supplementary-material"}**). The presence of the exosomal marker protein TSG101 was determined by western blot (**Figure [S3](#SM0){ref-type="supplementary-material"}**). Exosome distribution images were taken with the Bruker Small Animal Optical Imaging System (In-Vivo Xtreme II; Billerica, MA, USA).

Real-time quantitative PCR (qPCR): To measure microRNA, total RNA was extracted using Tri-Reagent (Molecular Research Inc., Cincinnati, OH, USA). For synthesis of cDNA, 10 ng of total RNA that was enriched in small RNAs was reverse transcribed using an NCode miRNA cDNA synthesis kit (Exiqon, Vedbaek, Denmark). The expression of microRNA was measured as described [@B46]. Primers were purchased from Exiqon. The mouse U6 gene was used as the standard for evaluating the tissue expression of individual miRNAs. miR-103 was used to evaluate serum microRNA levels. The response or change in expression levels of individual miRs was calculated as the difference between the threshold values of the sham and CKD genes (ΔΔcq) [@B47], [@B48].

miRNA-Seq library preparation and sequencing was performed by the Genomics core of Yerkes National Primate Research Center of Emory University. The method is provided in "A detailed, expanded Methods" (supplement).

Luciferase Reporter Assay and Transfection: The luciferase reporter constructs containing the luciferase coding sequence fused to the 3\'-UTRs of *FoxO1* (*pLuc.miR-26a/FoxO1-3\'UTR*) were generated by the Emory Integrated Genomics Core. The transfection and luciferase assay was described before and is provided in "A detailed, expanded Methods" (supplement) [@B49].

Western blot analysis and histology staining**:** Proteins were lysed in RIPA buffer. Detection of protein expression by western blot was performed according to established protocols [@B50]. The western blot, immunofluorescence staining procedure and antibodies are listed in "A detailed, expanded Methods" (supplement). The histological analysis was performed in a blinded manner to avoid bias. All immunohistochemical analyses were repeated at least three times, and representative images are shown.

Echocardiographic Evaluations of Cardiac Function: Echocardiography was performed on lightly anesthetized mice (under 1-2% isoflurane, in oxygen) using a Vevo 3,100 ultrasound system (VisualSonics, Toronto, CA) as described previously [@B51]. LV dimensions were obtained using parasternal long-axis views by two-dimensional-sided M-mode imaging. The cursor was positioned perpendicular to the interventricular septum and at the level of the papillary muscles and posterior wall of the LV. An M-mode image obtained at a sweep speed of 100 mm/s was used to determine diastolic and systolic LV wall thicknesses, LV end-diastolic dimensions (LVDD) and LV end-systolic chamber dimensions (LVSD). Systolic function was calculated from LV dimensions as fractional shortening (FS), as follows: FS = (LVDD LVSD)/LVDD. Recording of echocardiographic images was performed in random order with respect to the treatment or control animals. The acquisition of images and evaluation of data were performed by independent operators who were blinded to the treatment.

Statistical analysis: Data are presented as the mean ± se. To identify significant differences between two groups, comparisons were made using the t-test. Differences with P values \< 0.05 were considered significant. For a comparison of more than two groups, one-way ANOVA was performed with a post hoc analysis using the Student-Newman-Keuls test. Differences with P values \< 0.05 were considered significant.
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![***miR-26a* was decreased in the heart and skeletal muscle of CKD mice. (A)** Small RNA libraries were prepared using a SeqMatic tailormix miRNA sample preparation kit. The adapter-ligated libraries were then enriched using PCR amplification followed by gel enrichment for the mature miRNA library. The libraries were quantified on a Qubit® 2.0 Fluorometer using the High Sensitivity dsDNA assay. The heat map showed that miR-26a (orange square) was decreased in serum exosomes from CKD mice compared with sham mice (n = 3/group). **(B)** Total RNA was extracted from skeletal muscle, heart, kidney, liver, intestine and lung of normal mice. The expression of *miR-26a-5p* was assayed by real-time qPCR. The bar graph shows microRNA expression from each organ. The results are normalized to U6 (Bars: mean ± se; n = 6/group). **(C)** Total RNA was extracted from the hearts of sham and CKD mice. The expression of *miR-26a-5p* was assayed by real-time qPCR at 8 weeks after CKD surgery. The bar graph shows microRNA from the heart of CKD mice compared with levels in sham mice (represented by 1-fold). The results are normalized to U6 (Bars: mean ± se; n = 9/group; ^\#^p\<0.05 vs. control). **(D)** Total RNA was extracted from skeletal muscle of sham and CKD mice. The expression of *miR-26a-5p* was assayed by real-time qPCR at 8 weeks after CKD surgery. The bar graph shows microRNA from the gastrocnemius muscle of CKD mice compared with levels in sham mice (represented by 1-fold). The results are normalized to U6 (Bars: mean ± se; n = 9/group; ^\#^p\<0.05 vs. control).](thnov09p1864g001){#F1}

![**Exosome-carried mediator induces insulin resistance in skeletal and cardiac muscle cells.** Cultured skeletal muscle satellite cells or cardiac H9C2 cells were treated with media containing 5% sham mouse serum (control) or 5% CKD mouse serum (uremia) for 24 hours. **(A)** Total RNA was extracted from satellite cells. The expression of *miR-26a-5p* in cells was assayed by real time qPCR. The bar graph shows *miR-26a-5p* from the uremic serum treatment group compared with the level in the control serum treatment group (represented by 1-fold). The results are normalized to U6 (Bars: mean ± se; n=8/group; ^\#^p\<0.05 vs. control serum). **(B)** Total RNA was extracted from cardiac H9C2 cells. The expression of *miR-26a-5p* in cells was assayed by real time qPCR. The bar graph shows *miR-26a-5p* from the uremic treatment group compared with the levels in the control serum treatment group (represented by 1-fold). The results are normalized to U6 (Bars: mean ± se; n=8/group; ^\#^p\<0.05 vs. control serum). **(C)** Protein was isolated from satellite cells. PTEN and Akt in cell lysates were measured by western blots from different groups of cells. The bar graph shows the fold change of each protein band compared with levels in control serum treatment group represented by 1-fold. (Bars: mean ± se; n = 8/group; ^\#^p\<0.05 vs. control serum). **(D)** Protein was isolated from H9C2 cells. TGFβ1 and Akt in cell lysates were measured by western blots. The bar graph shows the fold change of each protein band compared with levels in control serum treatment group represented by 1-fold. (Bars: mean ± se; n = 8/group; ^\#^p\<0.05 vs. control).](thnov09p1864g002){#F2}

![**Provision of *miR-26a-5p* in skeletal muscle attenuated CKD-induced muscle atrophy. (A)** Experiment procedure: Mice were divided into 4 groups: sham, CKD without exosome treatment, CKD with intramuscular injection of exosome-encapsulated microRNA control (Exo/ctrl) and CKD with intramuscular injection of exosome-encapsulated *miR-26a* (Exo/miR-26a) mice, once per week. **(B)** Total RNA was isolated from TA muscle of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The expression of *miR-26a-5p* in muscle was assayed by real time qPCR. The bar graph shows the expression levels of the three *miR-26a* in each group compared with levels in the sham mice (represented by 1-fold). The results are normalized to U6. (Bars: mean ± se; n=9/group; ^\#^p\<0.05 vs. sham and ^\*^p\<0.05 vs. CKD+Exo/ctrl). **(C)** The representative cross-sectional area of TA muscle of sham and CKD mice. Cryosections of TA muscles were immunostained with anti-laminin antibody. The bar graph shows the frequency distribution of fiber cross-sectional areas (µm^2^) in sham (orange) and CKD (blue) mice (n=6/group). **(D)** The representative cross-sectional area of TA muscle of CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The bar graph shows the frequency distribution of fiber cross-sectional areas in CKD plus Exo/Ctrl (blue) and CKD with Exo/miR-26a (orange) mice (n=6/group). **(E)** Akt, p-Akt, GSK-3β, pGSK-3β, FoxO1, pFoxO1, PTEN, TRIM63/MuRF1 and FBXO32/atrogin-1 were measured by western blot in CKD mice with or without *miR-26a*. The bar graph shows the fold change of each protein band (bottom panel) or ratio of phospho-protein to total protein (top panel) compared with levels in sham mice (represented by a line at 1-fold). GAPDH was used as a loading control (Bars: mean ± se; n=9/group; ^\*^p\<0.05 vs. CKD and ^\#^p\<0.05 vs. sham).](thnov09p1864g003){#F3}

![***miR-26a* was increased in the heart of mice with intramuscular injection of Exo/*miR-26a.* (A)** Exosomes were labeled with 1 μmol/l fluorescent lipophilic tracer DiR. Mice were injected in skeletal muscle with Exo/*miR-26a*. Fluorescent organ images were acquired using a Bruker Small Animal Optical Imaging System. Normal mice (right) were not injected; sham mice (middle) and CKD mice (left) were injected with Exo/*miR-26a* in the left TA muscle. The fluorescence in the heart and TA muscle was assessed at 7 days after injection. **(B)** The fluorescence intensity of the heart was acquired by a Bruker Small Animal Optical Imaging System at 7 days after injection. The control was no exosome injection. The bar graph shows fluorescence intensity in the heart. (Bars: mean ± se; n=6/group; ^\*^p\<0.05 vs. control, ^\#^p\<0.05 vs. sham). **(C)** Total RNA was isolated from the heart of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The expression of *miR-26a-5p* was assayed by real time qPCR. The bar graph shows *miR-26a* expression in hearts from each group compared with levels in sham hearts (represented at 1-fold). The results are normalized to U6. (Bars: mean ± se; n = 6/group; ^\#^p\<0.05 vs. sham, ^\#^p\<0.05 vs. CKD + Exo/ctrl). **(D)** Total RNA was isolated from serum exosomes of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The expression of *miR-26a-5p* was assayed by real time qPCR. The bar graph shows *miR-26a* expression in exosomes from each group compared with levels in sham exosomes (represented at 1-fold). The results are normalized to*miR-103*. (Bars: mean ± se; n = 6/group; ^\#^p\<0.05 vs. sham, ^\#^p\<0.05 vs. CKD + Exo/ctrl). **(E)** Exosomes were isolated from the serum of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice and lysed in RIPA buffer. The insulin signaling- and fibrosis-related proteins phosphorylated FoxO1, PTEN and TGF-β1 were measured by western blot. TSG101 is an exosome protein marker. All protein band densities are normalized to the appropriate GAPDH control. The bar graph shows total PTEN, total TGF-β1 and the ratio of phospho-FoxO1 to total FoxO protein. The fold change is compared to levels in the control plus Exo/miR-ctrl (represented by a line at 1-fold). (Bars: mean ± se; n=6/group; ^\*^p\<0.05 vs. CKD+Exo//ctrl and ^\#^p\<0.05 vs. sham).](thnov09p1864g004){#F4}

![**Intramuscular injection of Exo/*miR-26a* attenuated uremic cardiomyopathy in CKD mice. (A)** Representative Masson\'s Trichrome staining of hearts from sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The bar graph shows collagen (blue in staining) measured at 8-weeks using the Micro-suite Five Biological Software (Olympus, Melville, NY, USA). The results show the fold change compared to sham levels, represented as a dotted line at 1-fold (Bars: mean ± se; n = 6/group; ^\#^p\<0.05 vs. sham, ^\*^p\<0.05 vs. CKD with Exo/ctrl). **(B)** Representative cryosections of heart from the four different treatment groups were immunostained with a fibronectin antibody. The bar graph shows fibronectin measured at 8-weeks. Fold change reflects a comparison with sham levels, represented as a dotted line at 1-fold (Bars: mean ± se; n = 6/group; ^\#^p\<0.05 vs. sham, ^\*^p\<0.05 vs. CKD with Exo/ctrl). **(C)** Protein was isolated from the heart of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The fibrosis-related protein CTGF and collagen1A1 in heart lysates were measured by western blots from different groups of mice. The bar graph shows the fold change from sham mice, represented by a line at 1-fold. (Bars: mean ± se; n = 9/group; ^\#^p\<0.05 vs. sham, ^\*^p\<0.05 vs. CKD plus Exo/ctrl).](thnov09p1864g005){#F5}

![***miR-26a* limits insulin resistance by targeting FoxO1, leading to improved cardiac function. (A)** Insulin signaling protein markers Akt, p-Akt, GSK-3β, pGSK-3β, PTEN, FoxO1, and pFoxO1 were measured by western blot in the heart of sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice. The bar graph shows the fold change of each individual protein band or ratio of phospho-protein to total protein compared with levels in sham mice (represented by a line at 1-fold). GAPDH was used as a loading control (Bars: mean ± se; n=9/group; ^\#^p\<0.05 vs. sham, ^\*^p\<0.05 vs. CKD plus Exo/ctrl). **(B)** Binding of *miR-26a* to the 3\'-UTR of *FoxO1* inhibits *FoxO1* translation. H9C2 cells were transfected with luciferase pLuc-ctrl vector or the vector containing the 3\'-UTR of *FoxO1* (pMIR-*FoxO1*/3358 - 3364) or a vector containing a mutated 3\'-UTR of *FoxO1* (pMIR-mut-*FoxO1*). Cells were cotransfected with renilla luciferase as a transfection control. Cells were then transduced by adenovirus containing *miR-26a* precursor RNA (*miR-26a*) and control virus (miR-ctrl). Luciferase activity in cells that received the pLuc-ctrl (no target 3\'UTR) and miR-ctrl (sequence unrelated to *miR-26a*) was designated as 100%. The response to *miR-26a* is expressed as a percent relative to the control. Bars present the results from triplicate determinations. Data: mean ± se; n=9; ^\#^p\<0.05 vs. FoxO/3UTR + miR-ctrl. **(C)** Representative echocardiographic evaluations of cardiac function in sham, CKD, CKD plus Exo/ctrl and CKD plus Exo/*miR-26a* (Exo/*miR-26a*) mice are shown. Echocardiography was performed on lightly anesthetized mice (under 1-2% isoflurane, in oxygen) using a Vevo 3,100 ultrasound system (VisualSonics). The green line represents left ventricular end-diastolic dimensions, and the red line represents left ventricular end-systolic dimensions. Detailed information is provided in table [2](#T2){ref-type="table"}. **(D)** Comparison of *miR-26a* expression in Flag-Exo/*miR-26a*- and MSTP-Exo/*miR-26a*-injected mice. RNA was isolated from serum exosomes from sham and CKD mice treated with Flag-Exo/*miR-26a* and MSTP-Exo/*miR-26a*. The expression of *miR-26a-5p* was assayed by real-time qPCR. The bar graph shows the expression of *miR-26a* from each cohort compared with levels in sham plus Flag-Exo/*miR-26a* injection mice (represented at 1-fold). The results are normalized to *miR-103a*. (Bars: mean ± se; n=6/group). **(E)** RNA was isolated from the hearts of sham and CKD mice. The expression of *miR-26a-5p* was assayed by real-time qPCR. The expression of *miR-26a* from each cohort compared with levels in sham plus Flag-Exo/*miR-26a*-injected mice (represented at 1-fold). The results are normalized to U6. (Bars: mean ± se; n=6/group; ^\*^p\<0.05 vs. CKD + Flag-Exo/*miR-26a*, ^\#^p\<0.05 vs. sham + MSTP-Exo/*miR-26a*, ^&^p\<0.05 vs. Flag-Exo/*miR-26a*).](thnov09p1864g006){#F6}

###### 

Physiological parameters - body and muscle weights and BUN in various cohorts

                       Sham         CKD             CKD+Exo/ ctrl   CKD+Exo/ *miR-26a*
  -------------------- ------------ --------------- --------------- --------------------
  Baseline B.W. (g)    22.6 ± 1.9   22.7 ± 1.8      22.5 ± 2.3      22.9 ± 1.6
  Terminal B.W. (g)    24.2 ± 2.5   19.5 ± 3.8\*    20.5 ± 2.3\*    22.9 ± 2.6
  TA weight (mg)       35.1 ± 1.1   28.7 ± 0.4\*    28.8 ± 0.5\*    32.1 ± 0.6^\#^
  Soleus weight (mg)   10.5 ± 0.1   8.7 ± 0.2       8.1 ± 0.5\*     9.8 ± 0.8\*^\#^
  EDL weight (mg)      10.3 ± 0.2   8.9 ± 0.6       8.2 ± 0.7\*     9.7 ± 0.3\*^\#^
  BUN (mg/dL)          21.3 ± 4.3   88.9 ± 11.6\*   86.2 ± 8.7\*    72.3 ± 6.5\*

Data are presented as the mean ± se; P \< 0.05 is significant (^\*^*vs.* sham, ^\#^*vs.* CKD), n=12/group; B.W.: body weight; TA: tibialis anterior; EDL: extensor digitorum longus; BUN: blood urea nitrogen

###### 

Cardiac function evaluated by echocardiography

  --------------------------------------------------------------------------------------
                      Sham\       CKD\            CKD+Exo/ ctrl\   CKD+Exo/ *miR-26a*\
                      (n=5)       (n=5)           (n=5)            (n=5)
  ------------------- ----------- --------------- ---------------- ---------------------
  Heart weight (g)    0.14±0.01   0.17±0.03       0.18±0.04        0.15±0.01

  Heart/Body weight   5.78±0.51   8.72±0.86^\#^   8.78±0.71^\#^    6.55±0.49^\*^

  IVS-d (mm)          0.51±0.0    0.48±0.0        0.49±0.0         0.48±0.0

  LVEDD (mm)          3.71±0.1    4.01±0.0^\#^    4.11±0.0^\#^     3.83±0.0^\*^

  FW-D (mm)           0.50±0.0    0.47±0.0        0.46±0.0         0.48±0.0

  IVS-s (mm)          1.05±0.0    1.10±0.0        1.09±0.0         1.07±0.0

  LVESD (mm)          2.68±0.1    3.19±0.1^\#^    3.23±0.2^\#^     2.86±0.1^\*^

  FW-S (mm)           0.74±0.0    0.73±0.0        0.74±0.0         0.74±0.0

  LV Vol-d            58.94±3.1   70.66±1.6^\#^   71.33±1.8^\#^    62.33±2.5^\*^

  LV Vol-s            26.98±2.3   40.97±2.3^\#^   41.58±2.7^\#^    32.69±2.1^\*^

  %EF                 54.59±2.2   42.20±2.2^\#^   41.78±2.1^\#^    49.87±2.4^\*^

  FS                  27.85±1.5   20.49±1.2^\#^   19.55±1.1^\#^    25.61±1.4^\*^

  LV Mass             56.79±2.7   60.84±1.7       61.0±1.8         57.89±2.6
  --------------------------------------------------------------------------------------

^\#^P \< 0.05 vs. Sham; ^\*^P \< 0.05 vs. CKD+Exo-ctrl; IVS-d: interventricular septum diameter; LVEDD: left ventricular end-diastolic diameter; FW-D: free wall in diastole; IVS-s: interventricular septum in systole; LVESD: left ventricular end-systolic diameter; FW-S: free wall in systole; LV Vol-d: left ventricular volume in diastole; LV Vol-s: left ventricular volume in systole; %EF: % ejection fraction; FS: fractional shortening; LV Mass: left ventricular mass
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